# Tislelizumab Plus Chemotherapy as First-Line Treatment for Advanced Squamous NSCLC With Brain Metastases

> **NCT05207904** · PHASE2 · UNKNOWN · sponsor: **Sun Yat-sen University** · enrollment: 41 (estimated)

## Conditions studied

- Non-Small Cell Squamous Lung Cancer
- Brain Metastases

## Interventions

- **DRUG:** Tislelizumab, paclitaxel, Carboplatin

## Key facts

- **NCT ID:** NCT05207904
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-06-17
- **Primary completion:** 2022-12-30
- **Final completion:** 2023-06-30
- **Target enrollment:** 41 (ESTIMATED)
- **Last updated:** 2022-01-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05207904

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05207904, "Tislelizumab Plus Chemotherapy as First-Line Treatment for Advanced Squamous NSCLC With Brain Metastases". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05207904. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*